Lumos Diagnostics Holdings Ltd is widening the distribution of its rapid respiratory infection test, FebriDx, across 43 WellStreet Urgent Care locations in Georgia and Michigan. This expansion follows a preliminary trial at a single site, and the move signals a potential network-wide deployment across WellStreet's 163 centres within the next six to 12 months.
The accelerated rollout comes on the heels of the US Food and Drug Administration granting FebriDx a CLIA waiver, a crucial step that removes barriers to its use in various point-of-care medical settings. This regulatory clearance significantly broadens the test's market accessibility, allowing for application in an estimated 300,000 US healthcare facilities without requiring extensive lab infrastructure or specialized staff.
The company has also secured a US$5 million milestone payment, tied to the FDA's 510(k) clearance and CLIA waiver, which bolsters its immediate financial standing. However, the conversion of this pre-payment into actual revenue hinges on the volume of subsequent purchase orders.
Read More: Woman with rare clotting syndrome denied life-saving heart surgery in UK
Shifting Towards Scale
Lumos, an Australia-based diagnostics developer, targets urgent care and similar providers with FebriDx, aiming to improve the speed of clinical decision-making and antibiotic stewardship. The company sees this expanded adoption in decentralised care settings as a pivotal moment, potentially establishing a new standard for diagnostics in urgent care and influencing future contract negotiations.
The current expansion represents a substantial step up from prior pilot programs. Lumos's strategy appears to be focused on demonstrating widespread adoption within significant healthcare networks. If the current phase proves successful, the company anticipates full integration across WellStreet's network, transitioning FebriDx from a pilot to a standard offering.
Context and Recent Developments
This latest push into a larger segment of the US market follows a series of announcements from Lumos. These include receiving its largest-ever purchase order for FebriDx and confirmation of Medicare reimbursement coverage for the test from another entity. The company has also initiated a contract manufacturing agreement with Micro-Pak®, alongside plans for a paediatric study intended to further expand FebriDx's application.
Read More: DoorDash Delivery to White House: Was 'DoorDash Grandma' a Staged Event?
The CLIA waiver from the US FDA is particularly significant. It permits the test to be used in a wide array of healthcare environments, including physician offices, clinics, and urgent care centres, simplifying its implementation and thereby expanding its potential user base. This clearance is seen as a major determinant in the trajectory of FebriDx's sales growth within the US.
